The Effects of PeptiStrong and Whey on Muscle Function In Older Adults

April 30, 2026 updated by: Nuritas Ltd

The Effects of PeptiStrong and Low Dose Whey Protein Versus High Dose Whey Protein Alone on Muscle Function In Older Adults

Examining the effects of PeptiStrong and protein on muscle function in older adults

Study Overview

Detailed Description

The aim of this study is to compare two protein drinks containing whey protein (derived from milk) in healthy adults aged 60 to 85 years. One group will consume a standard whey protein drink (20g), while the other group will consume a drink with half the total protein dose (10g) made of whey protein and PeptiStrong, a fava bean hydrolysate containing bioactive peptides.

The study will assess whether the lower protein drink containing PeptiStrong will lead to equal or greater improvements than the standard drink in physical function, such as the ability to stand up from a chair, walk at a normal pace, maintain balance, and grip strength. The study will also examine markers related to inflammation, fatigue, and quality of life.

The intended value of this research is to improve understanding of how targeted nutritional strategies may help maintain or improve muscle function in older adults. The findings may help inform future nutritional recommendations and the development of practical dietary interventions aimed at supporting healthy ageing and independence.

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Men and women aged 60 to 85 years at the time of enrolment
  • Community-dwelling (living independently or with minimal assistance)
  • Able to walk independently (with or without a walking aid) and complete simple physical function tests (such as standing up from a chair and walking short distances)
  • Willing and able to attend two study visits at the research facility (baseline and end of study)
  • Willing and able to consume a protein drink containing whey protein (derived from milk) once daily for 30 days
  • Able to understand the study information and provide written informed consent

Exclusion Criteria:

  • Any known food allergy or intolerance to fava bean protein or milk protein
  • Diagnosed kidney disease or any medical condition where increased protein intake is contraindicated
  • Yes to any of the answers on the "Older Adult Functional Assessment Screening Questionnaire"
  • Individuals with implanted electronic devices
  • Current or recent (within the past 3 months) participation in another clinical research study involving a nutritional or exercise intervention
  • Conditions that significantly impair mobility or balance such that safe completion of the physical function tests is not possible

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PeptiStrong + whey protein
2.4g PeptiStrong (provides 1.6g protein) + 8.4g of whey protein = 10g total protein
Fava bean protein hydrolysate containing bioactive peptides mixed with whey protein as dry powder for drinkable protein shake
Active Comparator: Whey protein
20g whey protein
Whey protein as dry powder for drinkable protein shake

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hand Grip Strength via hand held dynamometer
Time Frame: Baseline to Week 4
Change from baseline to end of study in grip strength as assessed via hand held dynamometer
Baseline to Week 4

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Chair Stand Test - Part of short performance physical battery
Time Frame: Baseline to week 4
Change from baseline to end of study in physical function assessment via chair stands. This test measures the time taken to complete 5 sit-to-stand repetitions in seconds. A lower time (fewer seconds) = better performance. As part of the full short performance physical battery it is converted to a subscore of 0-4, where a higher score = better performance
Baseline to week 4
Gait Speed as part of short performance physical battery
Time Frame: Baseline to week 4
Change from baseline to end of study in physical function assessment assessed as time to walk a fixed distance in seconds and reporting in meters per second. Higher speeds indicate better performance. This is converted to a subscore of 0-4 within the full short performance physical battery
Baseline to week 4
6 Minute Walking Endurance Test
Time Frame: Baseline to week 4
Change from baseline to end of study in physical function and endurance assessed as the total distance walked in 6 minutes in meters. A greater distance reflects better walking endurance and functional capacity.
Baseline to week 4
Balance test as part of short performance physical battery
Time Frame: Baseline to week 4
Change from baseline to end of study in balance as assessed by the ability to hold three standing positions of increasing difficulty: side-by-side, semi-tandem, and tandem stance in seconds. Higher scores indicate better balance. The overall score is converted to a a sub-score of 0-4 within the full short performance physical battery.
Baseline to week 4
Balance assessment via force plates
Time Frame: Baseline to week 4
Change from baseline to end of study in balance as assessed via force plates
Baseline to week 4
Quality of Life via the Sarcopenia Quality of Life (SarQoL®) Questionnaire
Time Frame: Baseline to week 4
Change from baseline to end of study in quality of life as measured via subjective SarQOL questionnaire. The total score ranges from 0 to 100, with higher scores reflecting a higher quality of life.
Baseline to week 4
Fatigue via Multidimensional Fatigue Inventory Questionnaire
Time Frame: Baseline to week 4
Change from baseline to end of study in self-reported fatigue as assessed via multidimensional fatigue inventory questionnaire. This 20-item questionnaire covers five dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation, and Reduced Activity. Each subscale score ranges from 4 to 20, with higher scores indicating greater fatigue
Baseline to week 4
C-reactive protein (CRP) via blood test
Time Frame: Baseline to week 4
Change from baseline to the end of study in inflammatory marker C-reactive protein (CRP) in serum as mg/L
Baseline to week 4
Interleukins via blood test
Time Frame: Baseline to week 4
Change from baseline to the end of study in Interleukin inflammatory markers in serum as pg/mL
Baseline to week 4
Body composition: Muscle mass and body fat via bioelectrical impedance analysis
Time Frame: Baseline to week 4
Change from baseline to end of study in muscle mass and body fat as measured by bioelectrical impedance analysis in kilograms and % of total body weight
Baseline to week 4

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Graeme Close, Professor, Liverpool John Moore University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 6, 2026

Primary Completion (Estimated)

July 30, 2026

Study Completion (Estimated)

October 30, 2026

Study Registration Dates

First Submitted

March 30, 2026

First Submitted That Met QC Criteria

April 7, 2026

First Posted (Actual)

April 14, 2026

Study Record Updates

Last Update Posted (Actual)

May 6, 2026

Last Update Submitted That Met QC Criteria

April 30, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Protein Supplementation

Clinical Trials on PeptiStrong + whey protein

Subscribe